Indication intelligence, analysis and sector perception

RegMed Investors’ (RMi) closing bell: a breakdown of pricing as earnings’ season ramps-up

July 31, 2019 7:26pm

The close was positive with an A/D Line of 6/39 and 0 flat and 2 acquired of my 45 covered companies while the IBB (-0.66%) while the XBI (-1.23%) also closed down

July ends with 9 positive, 1 holiday and 13 negative closes;

Pre-open indications: 5 HITs and 0 MISS

Should have followed my “leads” yesterday and made a profit

Insight from what's a volatile climate!

Markets and indexes:

The Dow closed down -333.75 points or -1.23% to 26,864.27;
The S&P closed down -32.80 points or -1.09% at 2,980.38;
The NASDAQ was down -98.19 or -1.19% to 8,175.42;

The iShares NASDAQ Biotechnology (IBB) and the SPDR S&P ETF (XBI) indicators:

Wednesday the IBB closed down -0.66% while the XBI closed down -1.23%
Tuesday the IBB closed up +0.90% while the XBI closed up +1.51%
Monday the IBB closed up +0.09% while the XBI closed down -0.22%
Friday the IBB closed up +1.07% while the XBI closed up +1.81%

Henry’omics:

The sector took it in the shorts today ...

Markets dropped as Fed Chair Powell dampened hopes for further rate cuts later this year.

The Dow logged its biggest one-day decline since May 31 along with the S&P 500. The NASDAQ had it biggest one-day drop since late June.

The major indexes posted solid monthly gains despite Wednesday’s drop. The S&P 500 (+1.3%) and NASDAQ gained (+ 2.1%) in July while the Dow climbed 1% this month.

Pre-open post, “anticipating the reaction; waiting for the Fed decision; is it a fait accompli and priced into the market?”

Wednesday’s advance/decline line scenario of 45 covered companies:

The close was positive with an A/D Line of 6/37 and 0 flat and 2 acquired;

Pre-open indications: 1 HIT and 4 MISS

Pluristem (PSTI closed down -$0.26 – hit;
Solid Bioscience (SLDB closed down -$0.21 – hit;
CRSPER Therapeutics (CRSP closed down -$0.03 – hit;
Editas Medicine (EDIT closed down -$1.56 – hit;
ReNeuron (RENE.L ) closed up +$0.50 – hit;

Wednesday’s decliners:

bluebird bio (BLUE -$1.81 after Tuesday’s -$3.78 and Monday’s -$2.92;

BioMarin Pharmaceuticals (BMRN -$1.68 after Tuesday’s +$1.18);
Editas Medicine (EDIT -$1.56);
Regenxbio (RGNX -$1.50 after Tuesday’s-$1.57 and Monday’s -$2.25);
uniQure (QURE -$1.31 after Tuesday’s -$2.07, Monday’s -$3.53 and Friday’s -$1.35);

Wednesday’s incliners:

Spark Therapeutics (ONCE +$0.79);
ReNeuron (RENE.L +$0.50 after Tuesday’s -$1.50 and Monday’s +$5.00);
Ionis Pharmaceuticals (IONS +$0.33 after Tuesday’s +$1.20 and Monday’s +$0.40);
MiMedx (MDXG +$0.09);
Verastem Oncology (VSTM +$0.07);

The percentage (%) indicators:

Wednesday’s range of the 6 upside was +0.21% (RENE.L) to +4.90% (VSTM) while the 37 downside ranged from -0.06% (CRSP) to -7.56% (BTX);
Tuesday’s range of the 26 upside was +0.57% (ONCE) to +8.99% (SLDB) while the 18 downside ranged from -0.07% (ONVO) to -6% (ATHX);
Monday’s range of the 11 upside was +0.34% (EDIT) to +7.11% (PSTI) while the 31 downside ranged from -0.26% (CLLS) to -7.95% (CUR -$0.19);

Upside volume stats: to compare

Wednesday: 1 out of the 6 upside had higher than the 3 month average volume;
Tuesday: 4 out of the 26 upside had higher than the 3 month average volume;
Monday: 2 out of the 11 upside had higher than the 3 month average volume;

Downside volume stats: NOTICE

Wednesday: 8 out of the 37 downside had higher than the 3 month average volume;
Tuesday: 4 out of the 18 downside had higher than the 3 month average volume;
Monday: 6 out of the 31 downside had higher than the 3 month average volume;

0 flat – with 2 acquired (AST & OSIR) and the Spark Therapeutics’ (ONCE) acquisition by Roche still being delayed

July’s sessions end:

Wednesday closed NEGATIVE with 37 decliners, 6 advancers, 0 flat and 2 acquired (AST & OSIR);

Tuesday closed POSITIVE with 18 decliners, 26 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 31 decliners, 11 advancers, 1 flat and 2 acquired (AST & OSIR);

Friday closed POSITIVE with 9 decliners, 32 advancers, 2 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 32 decliners, 11 advancers, 0 flats and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 27 decliners, 14 advancers, 2 flats and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 23 decliners, 19 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 17 decliners, 24advancers, 2 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 38 decliners, 4 advancers, 1 flat and 2 acquired (AST & OSIR);

Thursday closed POSITIVE with 14 decliners, 27 advancers, 2 flat and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 20 decliners, 23 advancers, 0 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 27 decliners, 15 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed POSITIVE with 15 decliners, 26 advancers, 2 flats and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 22 decliners, 21 advancers, 0 flats and 2 acquired (AST & OSIR);

Thursday closed NEGATIVE with 26 decliners, 14 advancers, 3 flats and 2 acquired (AST & OSIR);

Wednesday closed POSITIVE with 25 decliners, 16 advancers, 2 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 29 decliners, 13 advancers, 1 flat and 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 24 decliners, 18 advancers, 1 flat and 2 acquired (AST & OSIR);

Friday closed NEGATIVE with 23 decliners, 19 advancers, 1 flat and 2 acquired (AST & OSIR);

Thursday was a holiday;

Wednesday closed POSITIVE with 10 decliners, 31 advancers, 2 flat and 2 acquired (AST & OSIR);

Tuesday closed NEGATIVE with 30 decliners, 11 advancers, 2 flat and 2 acquired (AST & OSIR);

Monday closed NEGATIVE with 23 decliners, 19 advancers, 1 flat and 2 acquired (AST & OSIR);

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors. All investments are subject to risks. Investors should consider investment objectives.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.

35 companies, 1 interpreter!

Insight, foresight and recommendation

My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.

My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.

Do you have an opinion you would like to share with us? We would like to hear from you.

Please e-mail us at hwm@regmedinvestors.com.

Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors with past experience in sell-side analysis, buy-side management, corporate management and due diligence.

RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.

The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.

The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.